Avenue Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Avenue Therapeutics's estimated annual revenue is currently $2M per year.
- Avenue Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Avenue Therapeutics has 13 Employees.
- Avenue Therapeutics grew their employee count by 0% last year.
Avenue Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and Member Board Directors | Reveal Email/Phone |
2 | Chief Financial Officer | Reveal Email/Phone |
3 | Director Quality and CMC Project Management | Reveal Email/Phone |
4 | Controller | Reveal Email/Phone |
Avenue Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Avenue Therapeutics?
Avenue Therapeutics, Inc. (NASDAQ: ATXI), a Fortress Biotech (NASDAQ: FBIO) Company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. IV tramadol may fill a gap in the acute pain market between IV acetaminophen/NSAIDS and IV conventional narcotics. Avenue is currently evaluating IV tramadol in a pivotal Phase 3 program for the management of postoperative pain.
keywords:N/A
N/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.8M | 13 | -19% | $9.6M |
#2 | $0.4M | 13 | -13% | $116.4M |
#3 | $0.4M | 13 | -28% | $12.6M |
#4 | $1.6M | 13 | N/A | N/A |
#5 | $1.6M | 13 | N/A | N/A |